AstraZeneca boost on positive trials
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.AstraZeneca set out positive data from trials of its latest cancer drugs yesterday, as it fights to improve its share of the market for treatments of the disease. But doctors in the US declined to recommend extended uses for its promising breast cancer drug until more information is available.
The company said that Arimidex, already a treatment of advanced breast cancer in post-menopausal women, was much safer than Tamoxifen currently the "gold standard" for treatment in the early stages of the disease.
Arimidex is 10 times as expensive as Tamoxifen, an AstraZeneca product that has lost patent protection, and is associated with cancer of the womb. The Arimidex data, presented to the American Society of Clinical Oncology in Florida yesterday, suggests that Arimidex users are five times less likely to develop cancer of the womb than users of Tamoxifen.
However, a panel of doctors reporting to the conference said they would continue to recommend Tamoxifen as the drug of choice for early breast cancer, since no "compelling and mature data" existed on Arimidex or similar drugs.
The company also yesterday presented data for Iressa, another cancer product due on the market next year. It said trials found Iressa could shrink tumours in people suffering from lung cancer.
Cancer is one of the main battlegrounds in AstraZeneca's fight to grow earnings as its most successful drug ever the ulcer treatment, Losec is threatened with competition from cheap, copycat rivals. Daily sales of Losec were £10m last year.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments